Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance
Open Access
- 19 January 2020
- journal article
- research article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 24 (5) , 2942-2955
Abstract
Chronic myeloid leukaemia (CML) is a clonal myeloproliferative stem cell disorder characterized by the constitutively active BCR‐ABL tyrosine kinase. The LIM and SH3 domain protein 1 (LASP1) has recently been identified as a novel BCR‐ABL substrate and is associated with proliferation, migration, tumorigenesis and chemoresistance in several cancers. Furthermore, LASP1 was shown to bind to the chemokine receptor 4 (CXCR4), thought to be involved in mechanisms of relapse. In order to identify potential LASP1‐mediated pathways and related factors that may help to further eradicate minimal residual disease (MRD), the effect of LASP1 on processes involved in progression and maintenance of CML was investigated. The present data indicate that not only overexpression of CXCR4, but also knockout of LASP1 contributes to proliferation, reduced apoptosis and migration as well as increased adhesive potential of K562 CML cells. Furthermore, LASP1 depletion in K562 CML cells leads to decreased cytokine release and reduced NK cell‐mediated cytotoxicity towards CML cells. Taken together, these results indicate that in CML, reduced levels of LASP1 alone and in combination with high CXCR4 expression may contribute to TKI resistance.Keywords
Funding Information
- Deutsche Krebshilfe (70112142)
- Deutsche Krebshilfe (70112717)
This publication has 45 references indexed in Scilit:
- Minimal Residual Disease Eradication in CML: Does It Really Matter?Current Hematologic Malignancy Reports, 2017
- Treatment-free remission in patients with chronic myeloid leukemiaInternational Journal of Hematology, 2017
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2017
- Cessation of Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response: Results of the Euro-Ski TrialBlood, 2016
- Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IVBlood, 2015
- An update on the LIM and SH3 domain protein 1 (LASP1): a versatile structural, signaling, and biomarker proteinOncotarget, 2014
- LASP1 is a novel BCR-ABL substrate and a phosphorylation-dependent binding partner of CRKL in chronic myeloid leukemiaOncotarget, 2014
- Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER studyBlood, 2013
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trialThe Lancet Oncology, 2010
- CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cellsMolecular Cancer Therapeutics, 2008